An International Ki67 Reproducibility Study

被引:482
作者
Polley, Mei-Yin C. [1 ]
Leung, Samuel C. Y. [2 ]
McShane, Lisa M. [1 ]
Gao, Dongxia [2 ]
Hugh, Judith C. [3 ]
Mastropasqua, Mauro G. [4 ]
Viale, Giuseppe [4 ,5 ]
Zabaglo, Lila A. [6 ]
Penault-Llorca, Frdrique [7 ,8 ]
Bartlett, John M. S. [9 ]
Gown, Allen M. [10 ]
Symmans, W. Fraser [11 ]
Piper, Tammy [12 ]
Mehl, Erika [2 ]
Enos, Rebecca A. [13 ]
Hayes, Daniel F. [14 ]
Dowsett, Mitch [15 ]
Nielsen, Torsten O. [2 ]
机构
[1] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2M7, Canada
[4] European Inst Oncol, Div Pathol & Lab Med, Milan, Italy
[5] Univ Milan, Milan, Italy
[6] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[7] Ctr Jean Perrin, Dept Pathol, Clermont Ferrand, France
[8] Univ Auvergne, Clermont Ferrand, France
[9] Ontario Inst Canc Res, Toronto, ON, Canada
[10] PhenoPath Labs, Seattle, WA USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[12] Western Gen Hosp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XU, Midlothian, Scotland
[13] EMMES Corp, Rockville, MD USA
[14] Univ Michigan, Ctr Comprehens Canc, Breast Oncol Program, Ann Arbor, MI 48109 USA
[15] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 24期
关键词
DIGITAL-IMAGE-ANALYSIS; EARLY BREAST-CANCER; NEUROENDOCRINE TUMORS; NEOADJUVANT ANASTROZOLE; POSTMENOPAUSAL WOMEN; PREDICTIVE-VALUE; LABELING INDEX; KI-67; PROLIFERATION; RECOMMENDATIONS;
D O I
10.1093/jnci/djt306
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
In breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 has potential use in both research and clinical management. However, lack of consistency across laboratories has limited Ki67s value. A working group was assembled to devise a strategy to harmonize Ki67 analysis and increase scoring concordance. Toward that goal, we conducted a Ki67 reproducibility study. Eight laboratories received 100 breast cancer cases arranged into 1-mm core tissue microarraysuone set stained by the participating laboratory and one set stained by the central laboratory, both using antibody MIB-1. Each laboratory scored Ki67 as percentage of positively stained invasive tumor cells using its own method. Six laboratories repeated scoring of 50 locally stained cases on 3 different days. Sources of variation were analyzed using random effects models with log2-transformed measurements. Reproducibility was quantified by intraclass correlation coefficient (ICC), and the approximate two-sided 95% confidence intervals (CIs) for the true intraclass correlation coefficients in these experiments were provided. Intralaboratory reproducibility was high (ICC 0.94; 95% CI 0.93 to 0.97). Interlaboratory reproducibility was only moderate (central staining: ICC 0.71, 95% CI 0.47 to 0.78; local staining: ICC 0.59, 95% CI 0.37 to 0.68). Geometric mean of Ki67 values for each laboratory across the 100 cases ranged 7.1% to 23.9% with central staining and 6.1% to 30.1% with local staining. Factors contributing to interlaboratory discordance included tumor region selection, counting method, and subjective assessment of staining positivity. Formal counting methods gave more consistent results than visual estimation. Substantial variability in Ki67 scoring was observed among some of the worlds most experienced laboratories. Ki67 values and cutoffs for clinical decision-making cannot be transferred between laboratories without standardizing scoring methodology because analytical validity is limited.
引用
收藏
页码:1897 / 1906
页数:10
相关论文
共 32 条
[1]
Ki67 Labeling Index in Neuroendocrine Tumors of the Gastrointestinal and Pancreatobiliary Tract To Count or Not to Count Is Not the Question, But Rather How to Count [J].
Adsay, Volkan .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (12) :1743-1746
[2]
[Anonymous], 2008, Multilevel and Longitudinal Modeling Using Stata, DOI DOI 10.1093/GERONI/IGZ038.1816
[3]
[Anonymous], 2011, Package 'lme4'. Linear mixed-effects models using S4 classes. R package version
[4]
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[5]
A modified large-sample approach to approximate interval estimation for a particular intraclass correlation coefficient [J].
Cappelleri, JC ;
Ting, N .
STATISTICS IN MEDICINE, 2003, 22 (11) :1861-1877
[6]
Invasive Breast Cancer [J].
Carlson, Robert W. ;
Allred, Craig ;
Anderson, Benjamin O. ;
Burstein, Harold J. ;
Carter, W. Bradford ;
Edge, Stephen B. ;
Erban, John K. ;
Farrar, William B. ;
Forero, Andres ;
Giordano, Sharon Hermes ;
Goldstein, Lori J. ;
Gradishar, William J. ;
Hayes, Daniel F. ;
Hudis, Clifford A. ;
Ljung, Britt-Marie ;
Mankoff, David A. ;
Marcom, P. Kelly ;
Mayer, Ingrid A. ;
McCormick, Beryl ;
Pierce, Lori J. ;
Reed, Elizabeth C. ;
Sachdev, Jasgit ;
Smith, Mary Lou ;
Somlo, George ;
Ward, John H. ;
Wolff, Antonio C. ;
Zellars, Richard .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (02) :136-222
[7]
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists [J].
Dowsett, M ;
Ebbs, SR ;
Dixon, JM ;
Skene, A ;
Griffith, C ;
Boeddinghaus, I ;
Salter, J ;
Detre, S ;
Hills, M ;
Ashley, S ;
Francis, S ;
Walsh, G ;
Smith, IE .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2477-2492
[8]
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group [J].
Dowsett, Mitch ;
Nielsen, Torsten O. ;
A'Hern, Roger ;
Bartlett, John ;
Coombes, R. Charles ;
Cuzick, Jack ;
Ellis, Matthew ;
Henry, N. Lynn ;
Hugh, Judith C. ;
Lively, Tracy ;
McShane, Lisa ;
Paik, Soon ;
Penault-Llorca, Frederique ;
Prudkin, Ljudmila ;
Regan, Meredith ;
Salter, Janine ;
Sotiriou, Christos ;
Smith, Ian E. ;
Viale, Giuseppe ;
Zujewski, Jo Anne ;
Hayes, Daniel F. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1656-1664
[9]
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031 [J].
Ellis, Matthew J. ;
Suman, Vera J. ;
Hoog, Jeremy ;
Lin, Li ;
Snider, Jacqueline ;
Prat, Aleix ;
Parker, Joel S. ;
Luo, Jingqin ;
DeSchryver, Katherine ;
Allred, D. Craig ;
Esserman, Laura J. ;
Unzeitig, Gary W. ;
Margenthaler, Julie ;
Babiera, Gildy V. ;
Marcom, P. Kelly ;
Guenther, Joseph M. ;
Watson, Mark A. ;
Leitch, Marilyn ;
Hunt, Kelly ;
Olson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2342-2349
[10]
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies [J].
Fasanella, S. ;
Leonardi, E. ;
Cantaloni, C. ;
Eccher, C. ;
Bazzanella, I. ;
Aldovini, D. ;
Bragantini, E. ;
Morelli, L. ;
Cuorvo, L. V. ;
Ferro, A. ;
Gasperetti, F. ;
Berlanda, G. ;
Dalla Palma, P. ;
Barbareschi, M. .
DIAGNOSTIC PATHOLOGY, 2011, 6